Background In a previous systematic review and meta-analysis, we assessed the efficacy
and safety of nonvitamin-K antagonist oral anticoagulants versus warfarin in patients with …

Atrial fibrillation (AF) is an important risk factor for thromboembolic events, and
anticoagulation therapy can reduce this risk. Vitamin K antagonists (VKAs), such as warfarin …

Non-vitamin K antagonist oral anticoagulants (NOACs)–dabigatran, rivaroxaban, apixaban
and edoxaban–are well established in terms of preventing stroke or systemic embolism in …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are a major advance for
stroke prevention in atrial fibrillation (AF). Use of the vitamin K antagonist (VKA), warfarin …

Objective We compared the effectiveness and safety outcomes of non-vitamin K antagonist
oral anticoagulants (NOACs) and warfarin in patients with AF and VHD, as these patients …

Background Although several meta‐analyses have examined the effects of off‐label
underdosing of nonvitamin K antagonist oral anticoagulants (NOACs) compared with their …

Importance The randomized clinical trials comparing nonvitamin K antagonist oral
anticoagulants (NOACs) vs warfarin largely focused on recruiting high-risk patients with …

The non-vitamin K antagonist oral anticoagulants (NOACs) were approved for non-valvular
atrial fibrillation (AF) but this term may be misnomer. Thus, the term non-mechanical and …

Abstract Approximately 1 in 3–4 patients presenting with an ischemic stroke will also have
atrial fibrillation (AF), and AF-related strokes can be effectively prevented using oral …

Aim Non‐vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …